Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. Cameron D, et al. Among authors: dowsett m. Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Lancet. 2017. PMID: 28215665 Free PMC article. Clinical Trial.
Aromatase inhibitors in breast cancer.
Smith IE, Dowsett M. Smith IE, et al. Among authors: dowsett m. N Engl J Med. 2003 Jun 12;348(24):2431-42. doi: 10.1056/NEJMra023246. N Engl J Med. 2003. PMID: 12802030 Review. No abstract available.
Circulating tumour cells in breast cancer.
Ring A, Smith IE, Dowsett M. Ring A, et al. Among authors: dowsett m. Lancet Oncol. 2004 Feb;5(2):79-88. doi: 10.1016/S1470-2045(04)01381-6. Lancet Oncol. 2004. PMID: 14761811 Review.
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Dowsett M, et al. J Clin Oncol. 2005 Apr 10;23(11):2477-92. doi: 10.1200/JCO.2005.07.559. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767642 Clinical Trial.
Mechanisms of resistance to aromatase inhibitors.
Dowsett M, Martin LA, Smith I, Johnston S. Dowsett M, et al. J Steroid Biochem Mol Biol. 2005 May;95(1-5):167-72. doi: 10.1016/j.jsbmb.2005.04.022. J Steroid Biochem Mol Biol. 2005. PMID: 15982868 Review.
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group. Smith IE, et al. Among authors: dowsett m. J Clin Oncol. 2005 Aug 1;23(22):5108-16. doi: 10.1200/JCO.2005.04.005. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998903 Clinical Trial.
Proliferation marker Ki-67 in early breast cancer.
Urruticoechea A, Smith IE, Dowsett M. Urruticoechea A, et al. Among authors: dowsett m. J Clin Oncol. 2005 Oct 1;23(28):7212-20. doi: 10.1200/JCO.2005.07.501. J Clin Oncol. 2005. PMID: 16192605 Review.
740 results